OncRef

Clinical Trial: NCT03682289

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Rahul Aggarwal
Information Provided By:University of California, San Francisco
Last Update Posted:2026-04-23

Study Overview

Brief Summary

This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib or durvalumab may work better in treating participants with solid tumors.

Official Title

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

Conditions

Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer

Intervention / Treatment

  • Drug: Ceralasertib
  • Drug: Olaparib
  • Drug: Durvalumab

Other Study ID Numbers

  • 189510
  • NCI-2018-01648

Start Date (Actual)

2019-01-17

Primary Completion Date (Estimated)

2028-03-31

Study Completion Date (Estimated)

2028-03-31

Enrollment (Actual)

83

Study Type

Interventional

Phase

Phase 2